Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Amylyx (AMLX) To Contact Him Directly To Discuss Their Options
If you purchased or acquired common stock in Amylyx Pharmaceuticals, Inc. between November 11, 2022 to November 8, 2023 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on behalf of long-term stockholders following a class action complaint that was filed against Amylyx on July 1, 2025 with a Class Period from November 11, 2022 to November 8, 2023. Our investigation concerns whether the board of directors of Amylyx have breached their fiduciary duties to the company.
The complaint alleges that during the Relevant Period, however, the Individual Defendants, in breach of their fiduciary duties owed to Amylyx, willfully or recklessly made and/or caused the Company to make false and misleading statements regarding the success of the Relyvrio commercial launch. Specifically, the Individual Defendants willfully or recklessly made and/or caused the Company to make false and misleading statements that failed to disclose, inter alia, that: (1) that the purported “significant demand” for the drug was driven by an initial, temporary surge of patients that had already stabilized, thereby eliminating any realistic prospect for continued growth; (2) within months of Relyvrio’s launch, this initial surge had already subsided; (3) accordingly, there was no meaningful growth potential among newly diagnosed ALS patients within ALS treatment centers; (4) there was no viable opportunity for expansion beyond these specialized centers into the broader neurology community; (5) at the same time, Relyvrio was experiencing high, undisclosed discontinuation rates, which materially undermined the drug’s commercial viability; and (6) those undisclosed discontinuations had artificially inflated the perceived “runway” for acquiring new net patient starts. As a result of the foregoing, the Company’s public statements were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you are a long-term stockholder of Amylyx, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
